3GANSON N J, KELLY S J, SCARLETF E, et al. Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly ( ethylene glycol ) ( PEG ), in a phase I trial of subcutaneous pegylated urate oxidase [ J ]. Arthritis Res Ther,2006,8 (1) :R12.
4SUNDY J S, GANSON N J, KELLY S J, et al. Pharmacokinetics and pharmacodynamics of intravenous pegylated recombinant mammalian urate oxidase in patients with refractory gout [ J ]. Arthritis Rheum, 2007,56 ( 3 ) : 1021 - 1028.
5SUNDY J S, BECKER M A, BARAF H S, et al. For pegloticase phase 2 study investigators, reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase ) in patients with treatment-failure gout:results of a phase II randomized study [J]. Arthritis Rheum, 2008,58 ( 9 ) : 2882-2891.
6YUE C S, HUANG W, ALTON M, et al. Population pharmacokinetic and pharmacodynamic analysis of pegloticase in subjects with hyperuricemia and treatment-failure gout [ J ]. J Clin Pharmacol,2008,48 (6) :708-718.
7CHRISTOPHER M B, ROBERT L W . Gout therapeutics: new drugs for an old disease [ J ]. Lancet, 2011,377 (9760) : 165-177.
5European Medicines Agency.EPARs for authorised medicinal products for human use[EB/OL].(2011-01-01)[2011-01-O1].http://www.emea.europa.eu/htms/human/epar/a.htm.
3Moran ME. Uric acid stone disease [ J]. Front Biosci, 2003, 1 (8) : S1339-S1355.
4Ben-Dov IZ, Kark JD. Serum uric acid is a GFR-independent long- term predictor of acute and chronic renal insufficiency: the Jerusalem Lipid Research Clinic cohort study [ J ]. Nephrol Dial Transplant, 2011, 26(8): 2558-2566.
6Uchida S, Takahashi M, Sugawara M, et al. Effects of the N/L- type calcium channel blocker cilnidipine on nephropathy and uric acid metabolism in hypertensive patients with chronic kidney disease (J-CIRCLE Study) [ Jl. J Clin Hypertens (Greenwich), 2014, 16 (10) : 746-753.
8Hou SX, Zhu WJ, Pang MQ, et al. Protective effect of iridoid glycosides from Paedefia scandens ( LOUR. ) MERRILL (Rubiaceae) on uric acid nephropathy rats induced by yeast and potassium oxonate [ J]. Food Chem Toxieol, 2014, 64: 57-64.
9Chen L, Yin H, Lan Z, et al. Anti-hyperuficemic and nephroprotective effects of Smilax china L [ J ]. J Ethnopharmacol, 2011, 135(2): 399-405.
10Wang C, Pan Y, Zhang QY, et al. Quereetin and allopurinol ameliorate kidney injury in STZ-treated rats with regulation of renal NLRP3 inflammasome activation and lipid accumulation [J ]. PloS One, 2012, 7(6) : e38285.
